HVEM structures and mutants reveal distinct functions of binding to LIGHT and BTLA/CD160

Abstract
HVEM is a TNF (tumor necrosis factor) receptor contributing to a broad range of immune functions involving diverse cell types. It interacts with a TNF ligand, LIGHT, and immunoglobulin (Ig) superfamily members BTLA and CD160. Assessing the functional impact of HVEM binding to specific ligands in different settings has been complicated by the multiple interactions of HVEM and HVEM binding partners. To dissect the molecular basis for multiple functions, we determined crystal structures that reveal the distinct HVEM surfaces that engage LIGHT or BTLA/CD160, including the human HVEM–LIGHT–CD160 ternary complex, with HVEM interacting simultaneously with both binding partners. Based on these structures, we generated mouse HVEM mutants that selectively recognized either the TNF or Ig ligands in vitro. Knockin mice expressing these muteins maintain expression of all the proteins in the HVEM network, yet they demonstrate selective functions for LIGHT in the clearance of bacteria in the intestine and for the Ig ligands in the amelioration of liver inflammation.
Funding Information
  • U.S. Department of Energy (DE-AC02-98CH10886)
  • National Center for Research Resources (P41RR012408)
  • National Institute of General Medical Sciences (P41GM103473)
  • U.S. Department of Energy (DE-AC02-06CH11357)
  • Eli Lilly Company
  • Albert Einstein Cancer Center (P30CA013330)
  • National Institutes of Health (S10 OD020068)
  • Albert Einstein Macromolecular Therapeutics Development Facility
  • Price Family Foundation
  • Albert Einstein Center for Experimental Therapeutics
  • Pamela and Edward S. Pantzer
  • National Institutes of Health (P30CA023100)
  • National Institutes of Health (P30 DK120515)
  • National Institutes of Health (S10RR027366)
  • National Institutes of Health (U01 AI125955, P01 DK46763)
  • Academia Sinica